Jubilant Life Sciences Limited announced audited consolidated and standalone earnings results for the fourth quarter and year ended March 31, 2019. For the quarter, on a consolidated basis, the company reported total revenue from operations of INR 23,855.8 million compared to INR 22,519.6 million a year ago. Net loss for the period was INR 1,006.5 million compared to profit of INR 1,524.0 million a year ago. Basic and diluted earnings per share not annualized were INR 6.38 compared to INR 9.94 a year ago. For the full year, on a consolidated basis, the company reported total revenue from operations of INR 89,970.9 million compared to INR 75,578.1 million a year ago. Net profit for the period was INR 5,770.1 million compared to INR 6,344.2 million a year ago. Basic and diluted earnings per share not annualized were INR 36.86 compared to INR 41.25 a year ago. For the quarter, on a standalone basis, the company reported total revenue from operations of INR 8,651.2 million compared to INR 9,644.3 million a year ago. Net profit for the period was INR 74.4 million compared to INR 863.9 million a year ago. Basic and diluted earnings per share not annualized were INR 0.47 compared to INR 5.42 a year ago. For the full year, on a standalone basis, the company reported total revenue from operations of INR 34,386.1 million compared to INR 33,430.1 million a year ago. Net profit for the period was INR 1,476.3 million compared to INR 2,634.4 million a year ago. Basic and diluted earnings per share not annualized were INR 9.27 compared to INR 16.54 a year ago.